Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 124 of 1,261
  1. US 11958862

    Compounds and compositions and uses thereof

    PGI Drug Discovery LLC · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  2. US 11957754

    Clinical formulations

    Astellas Institute for Regenerative Medicine · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  3. US 11957684

    Treatment of heavy menstrual bleeding associated with uterine fibroids

    Takeda Pharmaceutical Company Limited · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  4. US 11957677

    Cancer treatment using FGFR inhibitors and PLK1 inhibitors

    Cardiff Oncology, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  5. US 11957736

    Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

    XERIS PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  6. US 11958849

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  7. US 11958840

    Compounds, compositions and methods

    DENALI THERAPEUTICS INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  8. US 11958845

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  9. US 11958850

    Heteroaryl compounds for kinase inhibition

    Takeda Pharmaceutical Company Limited · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  10. EP 4350345

    VERFAHREN ZUR VORHERSAGE, ERKENNUNG UND REDUZIERUNG VON ASPEZIFISCHER PROTEININTERFERENZ IN TESTS MIT VARIABLEN IMMUNGLOBULIN-EINZELDOMÄNEN

    ABLYNX NV [BE] · Granted Apr 10, 2024 · Expires Apr 5, 2044

    granted
  11. US 11951100

    Formulations of RBP4 inhibitors and methods of use

    Belite Bio, Inc · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  12. US 11951114

    Use of thyroid beta-agonists

    Viking Therapeutics, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  13. US 11952408

    HPV-specific binding molecules

    Editas Medicine, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  14. US 11952419

    Reagents and methods for treating cancer and autoimmune disease

    UNIVERSITY OF CONNECTICUT · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  15. US 11952600

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  16. US 11952376

    Substituted amino acids as integrin inhibitors

    Pliant Therapeutics, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  17. US 11952374

    Bicyclic compounds

    Aligos Therapeutics, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  18. US 11952370

    Selective ligands for modulation of GIRK channels

    Northwestern University · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  19. US 11952366

    Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases

    The Regents of the University of California · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  20. US 11952362

    Compositions and methods for treating epigenetic disease

    The Regents of the University of California · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  21. US 11951227

    Nanofiber structures and methods of use thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  22. US 11952352

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  23. US 11951176

    Stabilization of glucagon by trehalose glycopolymer nanogels

    The Regents of the University of California · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  24. US 11951206

    Cell housing device

    Vertex Pharmaceuticals Incorporated · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.